Internal Medicine, Hematology & Oncology · Baton Rouge, LA
NPI
1013995646
Since 2006
Specialty
Internal Medicine, Hematology & Oncology
Code 207RH0003X
Group practices
2
Medicare group memberships
Hospitals
3
Hospital affiliations
7777 Hennessy Blvd Ste 6000
Baton Rouge, LA, 70808
Phone (225) 757-0343
Groups this clinician bills Medicare through
Medicare paid, 2024
$2.9M
120,233 services
Medicare patients, 2024
426
Average age 75
Drug cost, 2024
$6.3M
1,801 prescriptions
Company payments, 2025
$3,916
From 43 companies
Procedures and visits billed to Original Medicare, 2024
In 2024, the most common Medicare service billed by Christopher M McCanless was code J0185 (injection, aprepitant, 1 mg), 5,460 times for 11 patients. In total Christopher M McCanless billed 120,233 services in 116 codes, and Medicare paid $2.9M.
| Code |
|---|
Official US government data: the national provider registry and Medicare enrollment records, linked by NPI. Last update of this record: 2024-10-03.
| Setting |
|---|
| Services |
|---|
| Patients |
|---|
| Paid per service |
|---|
| Medicare paid |
|---|
| J0185 Injection, aprepitant, 1 mg | Office | 5,460 | 11 | $1.34 | $7,322 |
| J0897 Injection, denosumab, 1 mg | Office | 4,380 | 16 | $20.35 | $89K |
| J1437 Injection, ferric derisomaltose, 10 mg | Office | 3,000 | 22 | $14.59 | $44K |
| J1100 Injection, dexamethasone sodium phosphate, 1 mg | Office | 2,078 | 40 | $0.09 | $186 |
| 36415 Venipuncture Blood Collection | Office | 1,202 | 352 | $8.52 | $10K |
| 85025 Blood Count | Office | 1,156 | 341 | $7.50 | $8,674 |
| 99214 Office E&M - Established | Office | 919 | 297 | $85.53 | $79K |
| J2469 Injection, palonosetron hcl, 25 mcg | Office | 820 | 18 | $0.76 | $622 |
| J2405 Injection, ondansetron hydrochloride, per 1 mg | Office | 464 | 18 | $0.07 | $34.19 |
| 96375 Injection Administration | Office | 370 | 47 | $10.80 | $3,997 |
| 96413 Chemotherapy Administration | Office | 252 | 43 | $85.62 | $22K |
| M0010 Enhancing oncology model (eom) monthly enhanced oncology services (meos) payment for eom enhanced services | Office | 209 | 34 | $72.26 | $15K |
| 96372 Injection Administration | Office | 143 | 34 | $8.82 | $1,261 |
| 99213 Office E&M - Established | Office | 113 | 89 | $58.46 | $6,606 |
| 96365 Intravenous Infusion, Hydration | Office | 106 | 45 | $40.78 | $4,323 |
By year: 2022 $3.0M for 188,596 services; 2023 $3.7M for 210,032 services; 2024 $2.9M for 120,233 services.
Lab tests billed to Medicare, 2024
| Test code | Tests | Patients | Paid per test | Medicare paid |
|---|---|---|---|---|
| 36415 Venipuncture Blood Collection | 1,202 | 352 | $8.52 | $10K |
| 85025 Blood Count | 1,156 | 341 | $7.50 | $8,674 |
Medicare prescription drug claims, 2024
In 2024, the drug Christopher M McCanless prescribed most often to Medicare patients was Anastrozole, with 118 prescriptions and refills. In total Christopher M McCanless wrote 1,801 Medicare prescriptions that cost $6.3M.
| Drug | Claims | 30-day fills | Patients | Cost |
|---|---|---|---|---|
| Anastrozole Generic | 118 | 305 | 37 | $2,182 |
| Eliquis Apixaban | 113 | 153 | 23 | $86K |
| Valacyclovir Valacyclovir Hcl | 86 | 111 | 17 | $2,509 |
| Hydroxyurea Generic | 80 | 131 | 18 | $1,421 |
| Ondansetron Hcl Generic | 70 | 70 | 36 | $517 |
| Letrozole Generic | 59 | 138 | 19 | $2,167 |
| Prednisone Generic | 58 | 58 | 16 | $204 |
| Gabapentin Generic | 57 | 75 | 15 | $561 |
| Levothyroxine Sodium Generic | 56 | 102 | 13 | $581 |
| Mirtazapine Generic | 52 | 80 | 14 | $526 |
| Hydrocodone-Acetaminophen Hydrocodone/Acetaminophen | 49 | 49 | 29 | $1,003 |
| Revlimid Lenalidomide | 49 | 49 | Under 11 | $851K |
| Escitalopram Oxalate Generic | 38 | 56 | 11 | $269 |
| Dexamethasone Generic | 38 | 49 | 16 | $534 |
| Pomalyst Pomalidomide | 36 | 36 | Under 11 | $812K |
Brand drugs: 578 claims; generic drugs: 1,223 claims; opioid claims: 106.
Money and other things of value reported by the companies
In 2025, drug and medical device companies paid Christopher M McCanless $3,916 ($3,916 in general payments such as food, travel and fees) from 43 companies. The largest payer was Novartis Pharmaceuticals Corporation with $446.
| Company | Payments | Amount |
|---|---|---|
| Novartis Pharmaceuticals Corporation NVS | 21 | $446 |
| AstraZeneca Pharmaceuticals LP AZN | 16 | $336 |
| Janssen Biotech, Inc. JNJ | 8 | $274 |
| Daiichi Sankyo Inc. 4568.T | 10 | $224 |
| Genzyme Corporation SNY | 9 | $196 |
| E.R. Squibb & Sons, L.L.C. BMY | 9 | $174 |
| PharmaEssentia USA Corporation 6446.TW | 6 | $160 |
| BeOne Medicines USA, Inc. ONC | 8 | $143 |
| Incyte Corporation INCY | 8 | $135 |
| Abbvie Inc. ABBV | 6 | $126 |
Official US government data on Original Medicare services, Medicare prescription drug plans and the payments drug and device companies must report. Services with fewer than 11 patients and drugs with fewer than 11 claims are not published. Procedure codes are shown by number with their public category.